Medicare, Medicaid plans to experiment with covering weight loss drugs

The Trump administration plans a five-year experiment, beginning in 2026/2027, to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs for obese Americans. This CMMI-led initiative, a notable policy shift, aims to expand access to these expensive medications, potentially costing Medicare $35 billion from 2026-2034, and includes mandatory lifestyle support. While representing a significant market opportunity for pharmaceutical firms like Novo Nordisk and Eli Lilly given the 100 million obese Americans, the proposal faces substantial cost concerns and uncertainties regarding state participation and long-term systemic affordability.

Analysis

The Trump administration is signaling a significant policy shift by planning a five-year experiment through the Center for Medicare and Medicaid Innovation (CMMI) to test coverage of GLP-1 drugs for obesity within Medicare and Medicaid, starting in 2026 and 2027 respectively. This move represents a potential long-term catalyst for GLP-1 manufacturers like Novo Nordisk and Eli Lilly by opening a pathway to a vast government-funded market, which includes an estimated 100 million obese Americans. However, the proposal is fraught with fiscal and political challenges. The estimated cost to Medicare alone is projected at $35 billion from 2026 to 2034, a figure that has drawn concern from officials like HHS Secretary Robert F. Kennedy Jr. and previously led insurers to lobby against such coverage. The experiment's design attempts to mitigate costs by mandating a "healthy lifestyle support system," including diet and exercise coaching, alongside the medication. Despite widespread staffing cuts, the administration's move to bolster CMMI with new hires suggests a firm commitment to this initiative. Nonetheless, its status as an experiment, coupled with uncertain state participation and mixed messaging from within the administration, introduces considerable uncertainty regarding the eventual scope and scale of GLP-1 coverage.

Key Decisions for Investors

• Investors should view this proposed experiment as a significant long-term de-risking event and a potential market expansion catalyst for GLP-1 manufacturers, primarily Eli Lilly and Novo Nordisk, warranting a bullish outlook on their long-term revenue potential.
• It is crucial to monitor the political developments and public feedback surrounding the CMMI model, as its high projected cost of $35 billion for Medicare presents a substantial fiscal hurdle that could lead to modifications or pushback.
• Consider the long-dated timeline of this catalyst, with the experiment not commencing until 2026-2027, meaning any material financial impact is several years away and contingent on the pilot's success and subsequent policy adoption.
• Watch for announcements on state and private Medicare plan participation, as their willingness to join the experiment will be a key early indicator of the program's viability and the ultimate size of the addressable market.